Trials / Conditions / Chronic Hepatitis C Virus

Chronic Hepatitis C Virus

20 registered clinical trials studyying Chronic Hepatitis C Virus.

Status	Trial	Sponsor	Phase
Completed	A Phase 2, Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects With Chronic HCV NCT05904470	Atea Pharmaceuticals, Inc.	Phase 2
Unknown	Efficacy Study to Evaluate the Effect of New Antiviral Drugs on HCV Infection. NCT02950870	University of Modena and Reggio Emilia	Phase 4
Completed	Drug Use-Results Survey in Participants Infected With Hepatitis C Virus Genotype 2 NCT02945228	AbbVie	—
Withdrawn	Study of Ombitasvir/Paritaprevir/Ritonavir in Japanese Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) NCT02806362	AbbVie	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Genotype 2 Chronic Hepa NCT02723084	AbbVie	Phase 3
Completed	A Study to Evaluate the Efficacy and Safety of ABT-493/ABT-530 in Japanese Adults With Chronic Hepatitis C Vir NCT02707952	AbbVie	Phase 3
Completed	Drug Use-results Survey in Patients Infected With Hepatitis C Virus Genotype 1 NCT02629172	AbbVie	—
Completed	Study of Efficacy and Safety of Grazoprevir (MK-5172)/Elbasvir (MK-8742) Combination Regimen for Treatment-Naï NCT02105467	Merck Sharp & Dohme LLC	Phase 3
Completed	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION- NCT01851330	Gilead Sciences	Phase 3
Completed	Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 1 NCT01852604	Merck Sharp & Dohme LLC	Phase 2
Completed	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subje NCT01768286	Gilead Sciences	Phase 3
Completed	Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of Velpatasvir in Partici NCT01740791	Gilead Sciences	Phase 1
Completed	Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects NCT01726517	Gilead Sciences	Phase 2
Withdrawn	SIMpill Medication Dispensing Device in the Treatment of HCV NCT01691235	University of Chicago	—
Completed	Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the T NCT01701401	Gilead Sciences	Phase 3
Completed	VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C NCT01581138	Vertex Pharmaceuticals Incorporated	Phase 2
Unknown	Prospective Clinical Study of the Role of the Immune Response, in Relation to Diet, in Patients Affected by Ei NCT02038387	University of Roma La Sapienza	N/A
Completed	A Study to Evaluate the Efficacy and Safety of Quadruple Therapy (VX-222, Telaprevir,Peginterferon-Alfa-2a, Ri NCT01516918	Vertex Pharmaceuticals Incorporated	Phase 2
Completed	Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard NCT01686789	King Abdulaziz Medical City	Phase 4
Completed	Study of T Cell Phenotype Activation Pathway in Human Alcoholic Liver Disease NCT00610597	Erasme University Hospital	—